← Every company
Regeneron Pharmaceuticals Inc Patents
What Regeneron Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
REGN on carbonthat →Filings on file
67
Granted
0
Still pending
67
Filed under
3 names
67 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEA61K 38/179, C07K 14/71, A61P 27/02, A61P 17/06, A61P 19/02, A61P 35/00, A61K 38/1866, C07K 1/06, C07K 1/113, C07K 1/16, C07K 1/165, C07K 1/18, C07K 1/20, C07K 1/22, C07K 1/36, C07K 16/22, C07K 16/28, C07K 16/283, C07K2317/622, C07K2319/30, C07K2319/33, C12N 5/0018, C12N 5/0031, C12N 15/66, C12N 15/85, C12N2529/10, C12N2800/10, C12P 21/02, C12P 21/06, C12Y 304/21004, G01N 30/80, G01N2030/027Filed as Regeneron Pharmaceuticals, Inc.2026-06-24Shunhai Wang | pending |
| SYSTEMS AND METHODS OF PH MODELING AND CONTROLG01N 21/77, G01N 27/4165, G01N 31/16, G01N 27/302, G01N 27/4167, G01N2201/12746Filed as Regeneron Pharmaceuticals, Inc.2026-06-10Ross BROWNE | pending |
| ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEA61K 38/179, C07K 14/71, A61P 27/02, A61P 17/06, A61P 19/02, A61P 35/00, A61K 38/1866, C07K 1/06, C07K 1/113, C07K 1/16, C07K 1/165, C07K 1/18, C07K 1/20, C07K 1/22, C07K 1/36, C07K 16/22, C07K 16/28, C07K 16/283, C07K2317/622, C07K2319/30, C07K2319/33, C12N 5/0018, C12N 5/0031, C12N 15/66, C12N 15/85, C12N2529/10, C12N2800/10, C12P 21/02, C12P 21/06, C12Y 304/21004, G01N 30/80, G01N2030/027Filed as Regeneron Pharmaceuticals, Inc.2026-06-08Shunhai Wang | pending |
| ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEA61K 38/179, C07K 14/71, A61P 27/02, A61P 17/06, A61P 19/02, A61P 35/00, A61K 38/1866, C07K 1/06, C07K 1/113, C07K 1/16, C07K 1/165, C07K 1/18, C07K 1/20, C07K 1/22, C07K 1/36, C07K 16/22, C07K 16/28, C07K 16/283, C07K2317/622, C07K2319/30, C07K2319/33, C12N 5/0018, C12N 5/0031, C12N 15/66, C12N 15/85, C12N2529/10, C12N2800/10, C12P 21/02, C12P 21/06, C12Y 304/21004, G01N 30/80, G01N2030/027Filed as Regeneron Pharmaceuticals, Inc.2026-06-08Shunhai Wang | pending |
| ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAMEA61K 38/179, C07K 14/71, A61P 27/02, A61P 17/06, A61P 19/02, A61P 35/00, A61K 38/1866, C07K 1/06, C07K 1/113, C07K 1/16, C07K 1/165, C07K 1/18, C07K 1/20, C07K 1/22, C07K 1/36, C07K 16/22, C07K 16/28, C07K 16/283, C07K2317/622, C07K2319/30, C07K2319/33, C12N 5/0018, C12N 5/0031, C12N 15/66, C12N 15/85, C12N2529/10, C12N2800/10, C12P 21/02, C12P 21/06, C12Y 304/21004, G01N 30/80, G01N2030/027Filed as Regeneron Pharmaceuticals, Inc.2026-06-08Andrew Tustian | pending |
| Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses ThereofC07K 16/2818, C07K 16/3092, A61P 35/00, A61K 39/3955, A61K2039/505, A61K2039/507, C07K 16/2809, C07K 16/3069, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/565, C07K2317/734, C07K2317/92Filed as Regeneron Pharmaceuticals, Inc.2026-06-04Andrew J. Murphy | pending |
| COMBINATION THERAPY TO TREAT BRAIN CANCERA61P 35/00, A61K 39/001195, A61K 39/001142, A61K 39/001157, A61K2039/80, A61K 39/001153, A61K 31/4188, A61K 39/39, A61K 39/39541, A61K 39/39558, A61K2039/505, A61K2039/53, A61K2039/54, A61K2039/545, A61K2039/55538, A61K2300/00, A61N 5/10, A61N2005/1098, C07K 16/2818Filed as Regeneron Pharmaceuticals, Inc.2026-06-01Amy-Lee Bredlau | pending |
| METHODS FOR CHARACTERIZATION OF VIRAL GENOME USING BASE MODIFICATIONSC12N 15/1065, C12Q 1/70, C12Q 1/6869, C12Q2525/117, C12Q2565/631Filed as Regeneron Pharmaceuticals, Inc.2026-05-26Steven Davis | pending |
| METHODS FOR REDUCING EOSINOPHILIC INFILTRATION BY ADMINISTERING AN ANTI-INTERLEUKIN-4 RECEPTOR (IL4R) ANTIBODYA61K 39/395, A61K 39/3955, C07K 16/2866, A61P 27/02, A61P 1/06, A61P 1/14, A61P 11/06, A61P 17/00, A61P 37/08, A61P 1/12, A61P 1/04, A61P 1/08, A61K 9/0019, A61K 31/56, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, A61K2039/577, C07K2317/21, C07K2317/565, C07K2317/76, C07K2318/00Filed as Regeneron Pharmaceuticals, Inc.2026-05-22Ana Kostic | pending |
| METHODS FOR DELIVERING AGENTS WITH PRE-FILLED SYRINGES TO MINIMIZE INTRAOCULAR INFLAMMATIONA61K 38/179, A61M 5/31, A61P 27/02, A61L2103/15, A61F 9/0017, A61L 2/208, A61M 5/001, A61M 5/178, A61M 5/31501, A61M 5/344, A61M2005/3139, A61M2005/5033Filed as Regeneron Pharmaceuticals, Inc.2026-05-12Nilsen MILLER | pending |
| METHOD FOR VIRAL INACTIVATIONC07K 1/22, C07K 1/36, C07K 1/34Filed as Regeneron Pharmaceuticals, Inc.2026-05-12John MATTILA | pending |
| DRUG DELIVERY DEVICE FIXTURE FOR TESTING SYSTEM AND METHODSA61M 5/008, A61M 5/19, A61M 5/24, A61M 5/3146, A61M 5/31528, A61M 5/3202, A61M2209/02, A61M2209/084Filed as Regeneron Pharmaceuticals, Inc.2026-05-11Trevor LANGLEY | pending |
| Single Immunoglobulin Interleukin-1 Receptor Related (SIGIRR) Variants And Uses ThereofC12Q 1/6883, C12Q2600/156, G01N2800/065Filed as Regeneron Pharmaceuticals, Inc.2026-05-08Claudia Gonzaga-Jauregui | pending |
| Lyophilized Formulations of AAV Drug ProductsA61K 9/19, A61K 48/0041, A61K 9/0019, A61K 9/1617, A61K 9/1623, A61K 9/1641, A61K 35/76, A61K 47/18, A61K 47/26, A61K 47/34Filed as Regeneron Pharmaceuticals, Inc.2026-05-04Dingjiang Liu | pending |
| METHODS AND COMPOSITIONS FOR TARGETED GENETIC MODIFICATION USING PAIRED GUIDE RNASA01K 67/0275, C12N 15/8509, C12N 15/907, C12N2310/20, C12N 9/222, A01K2227/105, C12N 9/22, C12N 15/102, C12N 15/113, C12Q 1/6888, C12Q2537/16Filed as Regeneron Pharmaceuticals, Inc.2026-04-22David Frendewey | pending |
| COMPOSITIONS AND METHODS COMPRISING SMALL NUCLEAR RNA (SNRNA) FOR TREATING GENETIC EPILEPSIESC12N 15/113, A61P 25/08, A61K 31/7088, C12N 15/86, C12N2310/11, C12N2310/531, C12N2320/33, C12N2330/51, C12N2750/14122, C12N2750/14143Filed as Regeneron Pharmaceuticals, Inc.2026-04-22Daniela ROTH | pending |
| Anti-SARS-CoV-2-Spike Glygoprotein Antibodies and Antigen-Binding FragmentsA61P 31/14, C07K 16/104, C12Q 1/701, C07K 16/102, A61K 39/215, A61K 39/395, A61K2039/505, A61K2039/507, C07K 16/10, C07K2317/21, C07K2317/24, C07K2317/34, C07K2317/73, C07K2317/732, C07K2317/76, C07K2317/92, C07K2317/94, C12Q2600/136, C12Q2600/156, G01N 33/56983, G01N2333/165, G01N2500/10Filed as Regeneron Pharmaceuticals, Inc.2026-04-17Alina Baum | pending |
| SYSTEM AND METHODS FOR SIMULATION OF MEDICAL DEVICESG06F 30/20, G06F2119/22, G06F2111/10, A61M 5/20, A61M 5/2033, A61M2205/70, A61M2205/702, G01N 3/08, G01N 3/22, G01N2203/0071, G01N2203/0075, G01N2203/0212, G01N2203/0222Filed as Regeneron Pharmaceuticals, Inc.2026-04-07Ross KENYON | pending |
| COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTSC07K 14/4711, C12N 5/0686, G01N 33/5088, A01K 67/0275, A01K2217/052, A01K2217/075, A01K2217/15, A01K2227/105, A01K2267/03, C07K2319/60, C07K2319/61, C12N 15/8509, C12N 15/86, C12N2510/04, C12N2750/00043, C12N2750/14143, G01N 33/6896, G01N2333/4709, G01N2500/10Filed as Regeneron Pharmaceuticals, Inc.2026-04-03Jeffery Haines | pending |
| Readily Isolated Bispecific Antibodies with Native Immunoglobulin FormatC07K 1/00, C07K 1/22, C07K 16/06, A61K 39/395, A61K2039/505, C07K 1/06, C07K 1/08, C07K 1/088, C07K 16/18, C07K 16/247, C07K 16/248, C07K 16/2809, C07K 16/2866, C07K 16/2887, C07K 16/46, C07K 16/461, C07K 16/468, C07K2317/21, C07K2317/31, C07K2317/52, C07K2317/526, C07K2317/56, C07K2317/76Filed as Regeneron Pharmaceuticals, Inc.2026-04-03Samuel Davis | pending |
| Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1C07K 16/244, C07K 16/2866, C12Q 1/6883, A61P 11/06, A61P 11/00, A61K2039/507, C07K2317/76, C12Q2600/106, C12Q2600/112, C12Q2600/156Filed as Regeneron Pharmaceuticals, Inc.2026-03-27Shannon Bruse | pending |
| ANTIBODIES TO HUMAN GDF8A61K 38/17, C07K 16/22, A61P 7/00, A61P 21/00, A61P 21/04, A61P 21/06, A61P 19/00, A61P 3/00, A61P 19/02, A61P 1/00, A61P 19/08, A61P 19/10, A61K 38/18, A61K 39/395, A61K 39/3955, A61K 47/42, A61K 48/00, A61K 49/16, A61K2039/505, C07K 14/435, C07K 14/475, C07K 16/18, C07K 16/28, C07K2317/21, C07K2317/565, C07K2317/567, C07K2317/76, C07K2317/92, C07K2317/94Filed as Regeneron Pharmaceuticals, Inc.2026-03-26Trevor Stitt | pending |
| Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsA61P 3/00, A61K 31/7105, A61K 48/00, A61P 9/10, A61P 1/16, A61P 9/00, A61P 3/04, A61P 3/06, A61P 3/10, A61P 9/12, A61P 9/04, A61K 31/7088, A61K 31/713, A61K 38/22, A61K 38/465, A61K 45/06, A61K2300/00, C12Q 1/6883, C12Q2600/156Filed as Regeneron Pharmaceuticals, Inc.2026-03-25Luca Andrea Lotta | pending |
| COMPOSITIONS AND METHODS COMPRISING SMALL NUCLEAR RNA (SNRNA) FOR TREATING DMDC12N 15/113, A61P 21/00, A61K 31/7105, C12N 15/86, C12N2310/531, C12N2320/33, C12N2330/51, C12N2750/14143Filed as Regeneron Pharmaceuticals, Inc.2026-03-24Rea LARDELLI MARKMILLER | pending |
| Methods of Treating Inflammatory ConditionsA61K 45/06, C07K 16/244, C07K 16/2866, A61P 37/00, A61P 17/06, A61P 11/06, A61P 17/00, A61P 19/02, A61P 37/08, A61P 1/00, A61P 11/00, A61P 25/00, A61P 29/00, A61P 1/04, A61P 9/14, A61P 11/02, A61K 38/1793, A61K 39/3955, A61K2039/505, A61K2039/507, A61K2039/54, A61K2039/545, C07K 14/7155, C07K2317/21, C07K2317/34, C07K2317/56, C07K2317/565, C07K2317/76, C07K2319/00, A61K2300/00Filed as Regeneron Pharmaceuticals, Inc.2026-03-23Jamie M. ORENGO | pending |
| RADIOLABELED MET BINDING PROTEINS FOR IMMUNO-PET IMAGINGA61K 51/103, C07K 16/2863, G01N 33/534, A61P 35/00, A61K 51/1093, C07K2317/21, C07K2317/31, C07K2317/565, C07K2317/73, C07K2317/76, C07K2317/77, C07K2317/92, C07K2317/94, G01N2333/71Filed as Regeneron Pharmaceuticals, Inc.2026-03-20Marcus Kelly | pending |
| ALLELE PREFERENTIAL RNAI OF MUTANT HUNTINGTIN (MTHTT) USING ALLELE-SPECIFIC INHIBITORY NUCLEIC ACID MOLECULESFiled as REGENERON PHARMACEUTICALS, INC.2026-03-20ELI A. STAHL | pending |
| ANTI-CD45 ANTIBODY-DRUG CONJUGATE PHARMACEUTICAL COMPOSITIONSA61K 47/6849, A61K 47/68035, A61K 47/6889, A61K 47/65, A61K 39/39591, A61K 47/02, A61K 47/20, A61K 47/22, A61K 47/26, C07K 16/289Filed as Regeneron Pharmaceuticals, Inc.2026-03-20Amit Katiyar | pending |
| NON-HUMAN ANIMALS THAT MAKE SINGLE DOMAIN BINDING DOMAINSFiled as REGENERON PHARMACEUTICALS, INC.2026-03-19CHUNGUANG GUO | pending |
| OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOFFiled as REGENERON PHARMACEUTICALS, INC.2026-03-17XIN XIA | pending |
| OLIGONUCLEOTIDE COMPOSITIONS AND USES THEREOF FOR INHIBITING DUX4 EXPRESSIONFiled as REGENERON PHARMACEUTICALS, INC.2026-03-17XIN XIA | pending |
| PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) T CELL RECEPTORS AND METHODS OF USE THEREOFA61K 38/1774, C07K 14/4748, C07K 14/7051, A61P 35/00, A61K 39/001189, A61K 35/17, A61K2039/5156, C07K 16/30, C07K 16/32, C07K2317/32, C07K2317/34, C07K2317/565, C07K2317/92, C12N 5/0636, C12N 15/625, C12N 15/86, C12N2740/10043Filed as Regeneron Pharmaceuticals, Inc.2026-03-16Natalie Bowerman | pending |
| PREDICTIVE MODELING OF DISSOLVED OXYGEN EXCURSIONS FOR REGULATING BIOREACTORFiled as REGENERON PHARMACEUTICALS, INC.2026-03-16KATHERINE RESCH | pending |
| PREDICTIVE MODELING OF DISSOLVED OXYGEN EXCURSIONS FOR REGULATING BIOREACTORFiled as Regeneron Pharmaceuticals, Inc.2026-03-15Katherine Resch | pending |
| ANTI-NEW YORK ESOPHAGEAL SQUAMOUS CELL CARCINOMA 1 (NY-ESO-1) ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFC07K 16/2833, C07K 16/3076, A61P 35/00, A61K2239/57, A61K2239/31, A61K2239/38, A61K 40/4269, A61K 40/31, A61K 40/11, A61K 31/7088, A61K 45/06, A61K2039/505, A61K2121/00, A61K2300/00, C07K 14/7051, C07K 14/70521, C07K 14/70578, C07K2317/24, C07K2317/32, C07K2317/34, C07K2317/565, C07K2317/622, C07K2317/71, C07K2317/92, C07K2319/02, C07K2319/03, C07K2319/33, C07K2319/74, C12N 5/0636, C12N2510/00Filed as Regeneron Pharmaceuticals, Inc.2026-03-13Kevin A. Bray | pending |
| METHODS AND SYSTEMS OF PROGNOSTIC MODELS THAT CAN PERFORM STOCHASTIC TIME-SERIES FORECASTINGFiled as REGENERON PHARMACEUTICALS, INC.2026-03-05ANDREW YANG | pending |
| ANTIGEN-BINDING MOLECULES THAT BIND CD38 AND/OR CD28, AND USES THEREOFC07K 16/2896, A61P 35/00, A61K 39/3955, A61K 45/06, A61K2039/505, A61K2039/507, A61K2039/545, C07K 16/2809, C07K 16/2818, C07K 16/2878, C07K 16/2887, C07K2317/21, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/565, C07K2317/73, C07K2317/75, C07K2317/76, C07K2317/92, C07K2317/94Filed as Regeneron Pharmaceuticals, Inc.2026-03-05David DiLillo | pending |
| DEVICES AND METHODS FOR PRECISION DOSE DELIVERYA61M 5/31, A61M 5/31501, A61M 5/31536, A61M 5/31583, A61M 5/3129, A61M 5/3146, A61M 5/31511, A61M 5/31526, A61M 5/31535, A61M 5/3155, A61M 5/31556, A61M 5/31558, A61M 5/31566, A61M 5/31568, A61M 5/31571, A61M 5/31573, A61M 5/31575, A61M 5/31581, A61M 5/31586, A61M 5/31593, A61M2005/3125, A61M2005/31508, A61M2005/3152, A61M2205/581, A61M2205/582, A61M2205/585Filed as Regeneron Pharmaceuticals, Inc.2026-03-04Sibgat ULLA | pending |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICEA01K 67/0278, C07K 14/70539, A01K2217/072, A01K2217/15, A01K2227/105, A01K2267/03, C07K2319/00Filed as Regeneron Pharmaceuticals, Inc.2026-03-04Lynn Macdonald | pending |
| VEGF TRAPS AND MINI-TRAPS AND METHODS FOR TREATING OCULAR DISORDERS AND CANCERC07K 14/71, A61K 47/65, A61P 27/02, A61P 27/06, A61P 35/00, A61K 38/00, C07K2317/53, C07K2319/30Filed as Regeneron Pharmaceuticals, Inc.2026-03-02William OLSON | pending |
| MAMMALIAN CELLS COMPRISING INTEGRATED CAS9 GENES TO PRODUCE STABLE INTEGRATION SITES, AND MAMMALIAN CELLS COMPRISING STABLE INTEGRATION SITES AND OTHER SITESC07K 14/005, C12N 5/0686, C12N 15/907, C12N2310/20, C12N 9/226, C12N 5/00, C12N 5/0682, C12N 9/22, C12N 15/11, C12N 15/635, C12N2510/00, C12N2750/14151, C12N2800/30, C12N2800/80, C12N2820/002, C12N2840/203Filed as Regeneron Pharmaceuticals, Inc2026-03-02Michael Goren | pending |
| METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONISTA61K 39/395, A61K 39/3955, C07K 16/2866, A61P 43/00, A61P 11/06, A61K 31/00, A61K 31/137, A61K 31/167, A61K 31/56, A61K 31/569, A61K 31/58, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/21, C07K2317/76, A61K2300/00Filed as REGENERON PHARMACEUTICALS, INC.2026-02-24Gianluca Pirozzi | pending |
| METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONISTA61K 39/395, A61K 39/3955, C07K 16/2866, A61P 43/00, A61P 11/06, A61K 31/00, A61K 31/137, A61K 31/167, A61K 31/56, A61K 31/569, A61K 31/58, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/21, C07K2317/76, A61K2300/00Filed as REGENERON PHARMACEUTICALS, INC.2026-02-24Gianluca Pirozzi | pending |
| HUMAN SERUM ALBUMIN IN FORMULATIONSA61K 9/0019, A61K 47/42, A61K 9/08, A61K 39/39591, A61K 47/26, A61K2039/505Filed as Regeneron Pharmaceuticals, Inc.2026-02-20Dorothy Kim | pending |
| METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) BY ADMINISTERING AN IL-4R ANTAGONISTC07K 16/2866, A61P 11/00, A61K 45/06, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/76Filed as REGENERON PHARMACEUTICALS, INC.2026-02-20Raolat Abdulai | pending |
| METHODS OF ANALYZING PROTEIN THERAPEUTICS UNDER NATIVE CONDITIONSFiled as REGENERON PHARMACEUTICALS, INC.2026-02-19WENJING PENG | pending |
| Treatment Of Psoriasis With Interferon Induced Helicase C Domain 1 (IFIH1) InhibitorsA61K 31/7088, A61K 48/00, C12N 15/113, C12Q 1/6883, C12N2310/20, A61P 17/06, A61K 31/7105, A61K 31/713, A61K 38/465, A61K 45/06, C12N 9/22, C12N 15/1137, C12N 15/1138, C12N2310/11, C12N2310/14, C12N2310/531, C12N2320/31, C12Q2600/118, C12Q2600/156, C12Y 203/02, C12Y 306/04013Filed as Regeneron Pharmaceuticals, Inc.2026-02-19Julie E. Horowitz | pending |
| Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) InhibitorsA61P 27/06, A61K 31/7088, C12N 15/113, C12N2310/20, C08G 69/10, C12N2310/11, C12N2310/14, C12N2310/531, C12N2320/30, C12N2320/34, C12Q 1/6883, C12Q2600/156Filed as Regeneron Pharmaceuticals, Inc.2026-02-19Kavita Praveen | pending |
| GENETICALLY MODIFIED ANIMALS COMPRISING HUMANIZED ANTIGEN PROCESSING AND PRESENTING MACHINERYFiled as REGENERON PHARMACEUTICALS, INC.2026-02-13ANDREW J. MURPHY | pending |
| PDCD-1 HOMING ENDONUCLEASE VARIANTSA61K 35/12, A61K 35/17, C12N 9/22, A61K 31/7105, A61K 35/14, A61K 38/00, A61K 38/465, A61K 48/00, A61K 48/005, C07K 14/70503, C07K2319/80, C12N 5/0636, C12N 15/52, C12N 15/85, C12N 15/907, C12N2510/00, C12N2750/14143, C12N2800/80Filed as REGENERON PHARMACEUTICALS, INC.2026-02-12Jordan JARJOUR | pending |
| Optimized Anti-CD3 Bispecific Antibodies and Uses ThereofC07K 16/28, C07K 16/2809, A61P 35/00, A61K2039/505, C07K 16/2863, C07K 16/3069, C07K 16/40, C07K 16/468, C07K2317/31, C07K2317/55, C07K2317/56, C07K2317/73, C07K2317/92Filed as Regeneron Pharmaceuticals, Inc.2026-02-11Eric Smith | pending |
| METHODS FOR GENERATING CONSENSUS SEQUENCE THAT PERMITS OPTIMIZED PRIMER DESIGNFiled as REGENERON PHARMACEUTICALS, INC.2026-02-10JARED ISAIAH RICHARDSON | pending |
| Treatment Of Inflammatory Bowel Disease In Subjects Having Loss-Of-Function (LOF) Gene VariantsC12Q 1/26, C12Q 1/6883, C12Q2600/106, C12Q2600/156, G01N2333/90241, G01N2800/065Filed as Regeneron Pharmaceuticals, Inc.2026-02-10Anna Alkelai | pending |
| GENETICALLY MODIFIED T CELL RECEPTOR MICEA01K 67/0278, C07K 14/7051, A01K2207/15, A01K2217/072, A01K2217/15, A01K2227/105, A01K2267/0387, C07K2319/00, C12N 5/0606, C12N 5/0636, C12N 15/8509, C12N2510/00, C12N2800/204, C12N2800/30Filed as Regeneron Pharmaceuticals, Inc.2026-02-06Lynn MACDONALD | pending |
| Anti-MUC16 Antibodies, Antibody-Drug Conjugates, and Bispecific Antigen-Binding Molecules that Bind MUC16 and CD3, and Uses ThereofG01N 33/5759, C07K 16/3092, A61K 47/6851, A61K 47/6869, A61K 47/6849, A61P 35/00, A61K 39/395, A61K 39/39558, A61K2039/505, C07K 16/2809, C07K 16/2863, C07K 16/3069, C07K 16/44, C07K 16/468, C07K2317/24, C07K2317/31, C07K2317/33, C07K2317/51, C07K2317/515, C07K2317/56, C07K2317/565, C07K2317/73, C07K2317/92, C07K2317/94, G01N 33/6854, G01N2333/705Filed as Regeneron Pharmaceuticals, Inc.2026-02-06Lauric Haber | pending |
| PROTEIN-ANTIVIRAL COMPOUND CONJUGATESA61K 47/6841, A61K 47/6801, A61K 47/6889, A61K 47/6839, A61K 47/6803, A61P 31/16, C07K 16/108, A61K 31/215, A61K 31/506, A61K 31/5383, A61K 45/06Filed as Regeneron Pharmaceuticals, Inc.2026-01-28Alina BAUM | pending |
| DRUG DELIVERY DEVICES, SAFETY SYSTEMS, TRAINING DEVICES, AND METHODS OF USE THEREOFG09B 23/285, A61M 5/2033, A61M 5/3129, A61M 5/3137, A61M 5/31501, A61M 5/31505, A61M 5/31511, A61M 5/31513, A61M 5/3157, A61M 5/3202, A61M 5/3204, A61M 5/3213, A61M 5/3243, A61M2005/2073, A61M2005/208, A61M2005/3139, A61M2005/3142, A61M2005/31508, A61M2005/3247, A61M2005/3267, A61M2205/581, A61M2205/582, A61M2205/583, A61M2205/70, A61M2209/02Filed as Regeneron Pharmaceuticals, Inc.2026-01-27Trevor LANGLEY | pending |
| DRUG DELIVERY DEVICES, SAFETY SYSTEMS, TRAINING DEVICES, AND METHODS OF USE THEREOFFiled as REGENERON PHARMACEUTICALS, INC.2026-01-27TREVOR LANGLEY | pending |
| RADIOLABELED ANTI-PD-L1 ANTIBODIES FOR IMMUNO-PET IMAGINGA61K 51/1045, C07K 16/2827, A61P 35/00, A61K 51/0474, A61K 51/1093, A61K2121/00, C07K 16/22, C07K 19/00, C07K2317/515, C07K2317/565, C07K2317/92Filed as Regeneron Pharmaceuticals, Inc.2026-01-26Marcus Kelly | pending |
| METHODS OF TREATING AUTOIMMUNE DISEASES BY ADMINISTERING BISPECIFIC CD20XCD3 ANTIBODIESFiled as REGENERON PHARMACEUTICALS, INC.2026-01-22AAFIA CHAUDHRY | pending |
| STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIESA61K 39/39591, C07K 16/22, A61P 3/00, A61P 9/00, A61P 3/06, A61P 35/00, A61K 9/0019, A61K 9/0021, A61K 9/08, A61K 39/3955, A61K 47/183, A61K 47/22, A61K 47/26, C07K2317/56, C07K2317/565, C07K2317/94Filed as Regeneron Pharmaceuticals, Inc.2026-01-21Dingjiang LIU | pending |
| ASSEMBLY LINE WITH INTEGRATED ELECTRONIC VISUAL INSPECTIONG06T 7/70, B65G 15/58, G06T 7/00, G06T 7/0008, G06T 7/231, G06T 7/74, G06T 7/73, G06T 7/223, G16H 40/67, G16H 40/63, G16H 20/13, G16H 40/60, B65G 43/08, B65G2201/02, B65G2201/0258, B65G2203/0241, B65G2203/041, G01N 21/89, G06Q 50/04, G06T 7/0006, G06T 7/001, G06T 7/60, G06T2207/10024, G06T2207/30108, G06T2207/30164, G06T2207/30242Filed as Regeneron Pharmaceuticals, Inc.2026-01-21Jason Eugene SMITH | pending |
| ANTI-PCRV ANTIBODIES THAT BIND PCRV, COMPOSITIONS COMPRISING ANTI-PCRV ANTIBODIES, AND METHODS OF USE THEREOFA61K 39/40, C07K 16/1214, A61P 31/04, A61K 45/06, A61K2039/505, A61K2039/507, C07K2317/21, C07K2317/51, C07K2317/515, C07K2317/56, C07K2317/565, C07K2317/76, C07K2317/92, C07K2317/94Filed as Regeneron Pharmaceuticals, Inc.2026-01-16Christos Kyratsous | pending |
| TREATMENT OF LIPID DISORDERS AND CARDIOVASCULAR DISEASES WITH PHOSPHOLIPASE A2 GROUP XIIB (PLA2G12B) INHIBITORSFiled as REGENERON PHARMACEUTICALS, INC.2026-01-15SARAH GRAHAM | pending |
| METABOLICALLY OPTIMIZED CELL CULTUREC07K 16/00, C07H 21/04, C07K2317/14, C12N 5/0006, C12N 15/63, C12N2510/00, C12P 21/02, C12Q 3/00Filed as REGENERON PHARMACEUTICALS, INC.2026-01-15Shawn LAWRENCE | pending |
| GENETICALLY MODIFIED ANIMALS COMPRISING HUMANIZED ANTIGEN PROCESSING AND PRESENTING MACHINERYFiled as Regeneron Pharmaceuticals, Inc.2026-01-09Andrew J. Murphy | pending |
| GLP1R AGONIST-TETHERED GDF8 ANTIBODY CONJUGATES AND USES THEREOFFiled as REGENERON PHARMACEUTICALS, INC.2026-01-09AMY HAN | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on REGN
Company overviewEverything on REGN in one place, with the price.SEC filingsWhat REGN's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat REGN's own officers and directors buy and sell.Executive payWhat REGN awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in REGN.Funds holding itWhich funds and ETFs hold REGN, and how big a bet.LobbyingWhat REGN spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on REGN's account, and who they worked for.Federal contractsWhat federal agencies pay REGN.